

OCT 29 2009

510(k) Summary

Submitter:

OmniGuide, Inc.

One Kendall Square, Building 100 3rd Floor

Cambridge, MA 02139

Contact Person:

Douglas W. Woodruff

Telephone:

617-551-8404

Fax:

617-551-8445

Proprietary Name:

OmniGuide BeamPath® FELS 25A, CO₂ Laser System

Common Name:

CO₂ Laser Powered Surgical Instrument

Classification:

878.4810

Product Code:

GEX

Classification Name:

Laser surgical instrument for use in general and plastic

surgery and in dermatology.

Substantial Equivalence Claimed To:

K063698 C-Las CO₂ Laser System

Description:

The OmniGuide BeamPath FELS 25A, CO_2 Laser System, is a Carbon dioxide (CO_2) Laser emitting light at a wavelength of 10.6 μm . It has an RF excited laser tube which produces a maximum continuous wave (CW) output power of up to 30 watts. Laser energy (CO_2), with a wavelength of 10.6 μm , has a variety of attractive features for surgical use. Because it is strongly absorbed by water (the main constituent of biological tissue) it does not penetrate into tissue beyond the point of application of the laser energy. This small depth of penetration (0.1-0.2 mm) leads to high cutting precision and minimal thermal damage to adjacent tissue. In addition, the CO_2 wavelength has excellent coagulation capabilities

The laser console is a table top console which can be easily transported from one surgery room to the other. The controls for the physician are part of the console and the parameters are clearly displayed on a large screen display. The laser light is guided through different mirrors and focused via an attached adapter. The adapter is the interface allowing an OmniGuide BeamPath Fiber or equivalent to attach to the laser.

Materials used are mainly machined aluminum or stainless Steel and standard optics for the transmission or the reflection of the CO₂ laser wave length. Only the laser energy from the OmniGuide BeamPath FELS 25A, CO₂ Laser System comes in contact with the patient. The energy is guided through a hollow waveguide such as the OmniGuide BeamPath hollow waveguide fiber. It is worth noting that all components (mirrors, lenses and the fiber) that the CO₂ light travels though are passive and do not alter the wavelength or any other of the fundamental properties or beneficial attributes of the CO₂ Laser.

Indications for Use:

The OmniGuide BeamPath FELS 25A, CO₂ Laser System is indicated for the incision, excision, ablation, vaporization and coagulation of body soft tissues in the following specialties:

- Dermatology
- General Surgery
- Gynecology
- Head & Neck Surgery
- Neurosurgery
- Oral Surgery
- Orthopedic Surgery
- Otorhinolaryngology
- Pediatric Surgery
- Plastic & Reconstructive Surgery
- Podiatry

Urology

Intended Use:

The OmniGuide BeamPath® FELS 25A, CO₂ Laser System intended to be used in conjunction with the OmniGuide BeamPath Adapter and the OmniGuide BeamPath fiber and is intended to be used for the incision, excision, ablation, vaporization and coagulation of body soft tissues including intra-oral tissues.

Summary of Technological Characteristics:

The device is a 30 watt maximum power CO₂ laser, emitting wavelength of 10.6 μm. The System incorporates an adapter that allows the connection to CO₂ waveguide fibers such as the OmniGuide BeamPath WaveGuide Fiber, to transmit the laser energy to the surgical site.

Performance Data:

Non-clinical Performance Data: The OmniGuide BeamPath® FELS 25A, CO₂ Laser System performance characteristics have been evaluated through testing and analysis of laser power output and beam quality. This type of testing complies with the respective section of the FDA Guidance on the Content and Organization of a Premarket Notification for a Medical Laser (1995) and is similar to the predicate device tests. The performance of OmniGuide BeamPath® FELS 25A, CO₂ Laser System and related parameters of the predicate device are the same.

<u>Clinical Performance Data</u>: Formal clinical trials were not deemed necessary as the device is using the same technology and intended use as predicate device.

Conclusions Drawn from Tests and Analysis: The intended use and major performance parameters of the OmniGuide BeamPath® FELS 25A, CO₂ Laser System are equivalent to the characteristics of above mentioned legally marketed device.





Food and Drug Administration 10903 New Hampshire Avenue Document Control Room W-066-0609 Silver Spring, MD 20993-0002

OmniGuide, Inc. % Regulatory Technology Services, LLC Mr. Mark Job 1394 25th Street, Northwest Buffalo, Minnesota 55313

OCT 2 9 2009

Re: K093251

Trade/Device Name: OmniGuide BeamPath® FELS 25A, CO₂ Laser System

Regulation Number: 21 CFR 878.4810

Regulation Name: Laser surgical instrument for use in general and plastic surgery

and in dermatology

Regulatory Class: Class II

Product Code: GEX

Dated: October 15, 2009 Received: October 16, 2009

Dear Mr. Job:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/cdrh/mdr/ for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson

Director

Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

Indications for Use

Not yet assigned 12093251

510(k) Number (if known):

mniGuide BeamPath® FEL	S 25A, CO₂ Laser System
	r System is indicated for the incision, f body soft tissues in the following
Surgery Surgery Sology Sology Sology Sology Sology Sology Sology Sology Sology	
XAND/OR	Over-The-Counter Use(21 CFR 801 Subpart C)
WRITE BELOW THIS LINE	-CONTINUE ON ANOTHER PAGE IF
rrence of CDRH, Office of D	Device Evaluation (ODE)
Sign-Off) of Surgical, Orthopedic, torative Devices	Page 1 of1
	AND/OR WRITE BELOW THIS LINE WRITE BELOW THIS LINE I R. Jan S. Sign-Off) of Surgical, Orthopedic, torative Devices